Johnson & Johnson to acquire Firefly Bio for $1 billion

Johnson & Johnson (NYSE:JNJ) announced today that it has entered into a definitive agreement to acquire Firefly Bio for $1 billion in cash.

The acquisition is intended to strengthen J&J’s oncology pipeline by integrating Firefly’s proprietary Firelink™ degrader antibody conjugate (DAC) platform, a novel therapeutic approach designed to address complex, hard-to-treat cancers.

The Firelink™ platform represents a significant evolution in antibody-based therapeutics.

Unlike traditional approaches, the technology is engineered to deliver highly selective protein degraders directly into tumor cells while sparing healthy tissue.

This targeted precision is particularly significant for patients with tumors driven by mutations in the KRAS gene—a target that has historically been considered "undruggable" due to its molecular structure, which lacks the binding sites typically required for conventional drug therapies.

The transaction, which has been approved by the boards of both companies, is expected to close later this year, subject to customary regulatory approvals and closing conditions.

By adding Firefly’s pipeline of preclinical candidates to its existing antibody engineering capabilities, Johnson & Johnson aims to accelerate the development of more durable and effective treatments for a variety of prevalent solid tumors.